FindTrial
Sign In

Morphine interaction with ticagrelor in ACS

Morphine interaction with ticagrelor in ACS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011867
Enrollment
Unknown
Registered
2017-07-04
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

morphin group:intravenous injection morphin 5mg
normal saline group:intravenous injection normal saline 5mg

Sponsors

The Second Hospital Of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged>18years; 2. Diagnostic criteria for AHA/ACC; 3. No antiplatelet therapy was received; 4. No active bleeding or clotting disorder; 5. No other serious disease; 6. The patient agrees to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. intake of non-steroidal anti-inflammatory drugs or platelet inhibitors; 2. known coagulation disorders; relevant impairment of renal or hepatic function; 3. chronic infectious diseases; 4. ontraindications for prasugrel or morphin.

Design outcomes

Primary

MeasureTime frame
Thrombelastogram;Platelet aggregation rate;Tigeralot concentration;—

Countries

China

Contacts

Public ContactTao Liu

The Second Hospital Of Hebei Medical University

liutaojiayouo@163.com+86 15032626675

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026